News
Myeloma Patients Europe (MPE) is pleased to announce that Denis Henrard, an experienced manager in the healthcare sector, has been appointed Chief Executive Officer (CEO). This follows last year’s news that the founding CEO of MPE, Ananda Plate, stood down from the role after ten very successful years.
The US Food and Drug Administration (FDA) has approved the CAR-T treatment ciltacabtagene autoleucel (also known as cilta-cel and marketed as Carvykti). Continue reading
Given the recent events on the world stage, we felt it was necessary to highlight our concern at the developing situation in Ukraine and to reiterate our support to patients, carers and our fellow patient advocacy groups within the country and in surrounding countries. Continue reading
Sandoz, a manufacturer of generic medicines, announced the launch of generic lenalidomide in 19 European countries. You can see the full press statement here.
Continue reading
Myeloma Patients Europe (MPE) is pleased to share that Hans Scheurer, President of MPE, will be acting as Interim Chief Executive Officer (CEO) until a permanent CEO is appointed in the coming months.
This follows last year’s news that the founding CEO of MPE, Ananda Plate, has stood down from the role after ten very successful years. Continue reading
As part of MPE’s Year of Action, we are excited to announce the launch of the survey on myeloma and AL amyloidosis diagnosis. At MPE, we know that early diagnosis significantly improves the outcomes and quality of life of patients and their experience of healthcare.
Today Myeloma Patients Europe (MPE) published our 2021: Year in Review, a snapshot of the major accomplishments from the past year.
In 2021, MPE launched two projects that will provide distinct and indispensable resources for the patient community: the launch of the redesigned Myeloma Access Atlas, helping the patient community to advocate more effectively for equal access to medicines, and the development of the European Myeloma Clinical Trial Navigator, which will significantly improve patients’ ability to make informed decisions about participation in clinical trials. These two projects usher in a new era of data-driven advocacy, true collaboration among multiple stakeholders to support patient organisations and the increase of transparency to empower individual patients. Continue reading
During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition a study was presented about a phase III trial for treating myeloma. This treatment supports the current three-drug standard of care with a fourth drug, a monoclonal antibody that is designed to fight cancer while also stimulating the immune system.
- Job Title: Medical and Scientific Officer
- Position Type: Full time/permanent
- Probation period: 6 months
- Travel Required: 15 days/year (approx.)
- Location: European Union (preferably Germany, Belgium or Spain) or United Kingdom/home-based
- Gross salary: 40.000 EUR/year
- Job Title: Chief Executive Officer
- Position Type: Full time/permanent
- Probation period: 6 months
- Travel Required: 30 days / year (approx.)
- Location: Europe (preferably Germany, Spain, Belgium or UK)